AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7048992 — intervention group
Group type: COMPARATOR
Intervention: PEEP = 0 cm H2O
Number of subjects: 12
Study 7048992 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP = 5 cm H2O
Number of subjects: 12
Study 7048992 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP = 10 cm H2O
Number of subjects: 12
Study 7048992 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP = 20 cm H2O
Number of subjects: 12
Study 7048992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary nonshunt flow (Qt‐Qs)
Number of subjects: 12
Study 31470829 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Plus intervention group
Number of subjects: 540
Study 31470829 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 540
Study 27893045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (thiazide-type diuretic)
Number of subjects: 22180
Study 27893045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone vs Lisinopril
Number of subjects: 22180
Study 27893045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone vs Amlodipine
Number of subjects: 22180
Study 27893045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone vs Lisinopril or Amlodipine (entire trial and posttrial follow-up)
Number of subjects: 22180
Study 25087908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (18 or 24 International Units), administered twice-daily for 8 weeks
Number of subjects: 50
Study 25087908 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray, administered twice-daily for 8 weeks
Number of subjects: 50
Study 24910215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation using the Sonoma Wrx device
Number of subjects: 64
Study 24910215 — intervention group
Group type: COMPARATOR
Intervention: Standard volar locking plate fixation
Number of subjects: 64
Study 22504044 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 1189
Study 19265481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study 19265481 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (first dose of vaccine)
Number of subjects: 0
Study 17506956 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational/informative intervention (booklet of information about prophylactic aspects and care of atopic dermatitis)
Number of subjects: 1247
Study 17506956 — intervention group
Group type: COMPARATOR
Intervention: Control group (current clinical practice)
Number of subjects: 1247
Study 14507259 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine loading (20 g.day(‐1) for 5 days, followed by 2 g.day(‐1) for 37 days)
Number of subjects: 20
Study 14507259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11324324 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial Laser Revascularization (TMR)
Number of subjects: 0
Study 11324324 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty and coronary artery bypass grafts
Number of subjects: 0
Study 9552772 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine (90 mg)
Number of subjects: 30
Study 9552772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (25 mg)
Number of subjects: 30
Study 9552772 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine (60 mg)
Number of subjects: 30
Study 9552772 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 7914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted red cells
Number of subjects: 871
Study 7914960 — intervention group
Group type: COMPARATOR
Intervention: Packed cells without buffy coat
Number of subjects: 871
Study 7914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Any blood transfusion
Number of subjects: 871
Study 7914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 871
Study 3288533 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 3288533 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study 28278742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 115
Study 28278742 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 115
Study 21745127 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management Program (WMP)
Number of subjects: 100
Study 21745127 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control Group)
Number of subjects: 100
Study 22434919 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) plus Cognitive Behavioral Therapy (CBT)
Number of subjects: 344
Study 22434919 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 344
Study 22434919 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 344
Study 20478449 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg)
Number of subjects: 40
Study 20478449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19213342 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied on acupoints Zhongliao (BL33) and Huiyang (BL35), for 30 min, once every two days for 4 weeks
Number of subjects: 93
Study 19213342 — intervention group
Group type: COMPARATOR
Intervention: Terazosin 2 mg taken orally once every evening for 4 weeks
Number of subjects: 93
Study 15671224 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron (125 mg FeSO4, 10 microg folate, 25 mg vitamin C)
Number of subjects: 81
Study 15671224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 microg folate and 25 mg vitamin C)
Number of subjects: 81
Study 12627414 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded sample size reassessment
Number of subjects: 0
Study 12627414 — intervention group
Group type: COMPARATOR
Intervention: Standard fixed sample size design
Number of subjects: 0
Study 10553500 — intervention group
Group type: EXPERIMENTAL
Intervention: RAGE GLY82SER variant
Number of subjects: 0
Study 10553500 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II haplotypes DRB1*0401-DQA1*0301-DQB1*0301
Number of subjects: 0
Study 10553500 — intervention group
Group type: COMPARATOR
Intervention: HLA class II haplotypes DRB1*1501-DQA1*0102-DQB1*0602
Number of subjects: 0
Study 8932539 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 30-mug bolus dose
Number of subjects: 0
Study 8932539 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 100-mug bolus dose
Number of subjects: 0
Study 8932539 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 300-mug bolus dose
Number of subjects: 0
Study 8932539 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 30-mug infusion dose
Number of subjects: 0
Study 8932539 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 100-mug infusion dose
Number of subjects: 0
Study 8932539 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 300-mug infusion dose
Number of subjects: 0
Study 8932539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1763292 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1 mg/100 ml
Number of subjects: 146
Study 1763292 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 2 mg/100 ml
Number of subjects: 146
Study 1763292 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 4 mg/100 ml
Number of subjects: 146
Study 1763292 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 25 mg/100 ml
Number of subjects: 146
Study 7045360 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 99
Study 7045360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 99
Study 31707153 — intervention group
Group type: EXPERIMENTAL
Intervention: Villalta scale for diagnosing PTS
Number of subjects: 88
Study 31707153 — intervention group
Group type: EXPERIMENTAL
Intervention: Villalta scale only
Number of subjects: 88
Study 31707153 — intervention group
Group type: COMPARATOR
Intervention: Clinical criteria only
Number of subjects: 88
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedophilic orientation with extrinsic non-offending motivation
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedophilic orientation with intrinsic non-offending motivation
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleiophilic orientation with extrinsic non-offending motivation
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleiophilic orientation with intrinsic non-offending motivation
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear
Number of subjects: 205
Study 29159755 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust, fear, and anger
Number of subjects: 205
Study 26979470 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activities (DA)
Number of subjects: 24
Study 26979470 — intervention group
Group type: COMPARATOR
Intervention: Inactivity (IA)
Number of subjects: 24
Study 26979470 — intervention group
Group type: COMPARATOR
Intervention: Heavy resistance exercise (RE)
Number of subjects: 24
Study 24739896 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg once every 2 weeks)
Number of subjects: 1010
Study 24739896 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (initial dose 400 mg/m2; 250 mg/m2 once a week thereafter)
Number of subjects: 1010
Study 23216943 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with etanercept and standardized HRQoL assessment and communication
Number of subjects: 0
Study 23216943 — intervention group
Group type: COMPARATOR
Intervention: Treatment with etanercept alone
Number of subjects: 0
Study 23216943 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL intervention (Skindex-29 assessment)
Number of subjects: 0
Study 20625364 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10-30 mg/9 hours
Number of subjects: 217
Study 20625364 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal system (PTS)
Number of subjects: 217
Study 17561494 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 70
Study 17561494 — intervention group
Group type: COMPARATOR
Intervention: Tilt training
Number of subjects: 70
Study 17561494 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 70
Study 17561494 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 15050334 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 15
Study 15050334 — intervention group
Group type: COMPARATOR
Intervention: Historical normal controls
Number of subjects: 15
Study 12492613 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulphate (600 mg) alone
Number of subjects: 10
Study 12492613 — intervention group
Group type: COMPARATOR
Intervention: Quinine sulphate (600 mg) plus troleandomycin (TAO; 500 mg every 8 h)
Number of subjects: 10
Study 9475328 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 microg b.i.d.)
Number of subjects: 21
Study 9475328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8565711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 37
Study 8565711 — intervention group
Group type: COMPARATOR
Intervention: Non-thrombolysis group
Number of subjects: 37
Study 2798924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 2798924 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 30766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (3 mg/day: 2 mg in the evening and 1 mg in the morning)
Number of subjects: 38
Study 30766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31514233 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg/d for 10 days, then 50 mg/d for 10 days, and 25 mg/d for 10 days)
Number of subjects: 60
Study 31514233 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (0.4 mg/kg/d for 15 days, then 0.2 mg/kg/d for 15 days)
Number of subjects: 60
Study 30992033 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 80
Study 30992033 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 80
Study 30992033 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS + Patient education
Number of subjects: 80
Study 30992033 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS + Patient education
Number of subjects: 80
Study 29251976 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.8 mg/g Spectrum cigarette
Number of subjects: 26
Study 29251976 — intervention group
Group type: COMPARATOR
Intervention: 5.2 mg/g Spectrum cigarette
Number of subjects: 26
Study 29251976 — intervention group
Group type: COMPARATOR
Intervention: 2.4 mg/g Spectrum cigarette
Number of subjects: 26
Study 29251976 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/g Spectrum cigarette
Number of subjects: 26
Study 26236924 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (600 mg/d)
Number of subjects: 120
Study 26236924 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (0.5 mg/d)
Number of subjects: 120
Study 23596887 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating renal blood circulation and ovarian stimulation formula
Number of subjects: 86
Study 23596887 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 86
Study 21502457 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen during anesthesia, followed by high‐flow oxygen for 2 hours in the recovery room
Number of subjects: 210
Study 21502457 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen, as usual
Number of subjects: 210
Study 19653763 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual stimulus pairs presented at various relative delays
Number of subjects: 0
Study 19653763 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual stimulus pairs with physical synchrony as a standard
Number of subjects: 0
Study 16998208 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT (computerized decision support system)
Number of subjects: 2326
Study 16998208 — intervention group
Group type: COMPARATOR
Intervention: Physician's treatment (control)
Number of subjects: 2326
Study 15585610 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine I 131 Tositumomab
Number of subjects: 78
Study 15585610 — intervention group
Group type: COMPARATOR
Intervention: unlabeled Tositumomab
Number of subjects: 78
Study 15585610 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine I 131 Tositumomab (crossover)
Number of subjects: 78
Study 15585610 — intervention group
Group type: COMPARATOR
Intervention: unlabeled Tositumomab (prior response)
Number of subjects: 78
Study 11740759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted low-dose warfarin (INR 1.4-1.8)
Number of subjects: 245
Study 11740759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (2 mg daily)
Number of subjects: 245
Study 9284597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 10
Study 9284597 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10
Study 8453847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone (750 mg)
Number of subjects: 12
Study 8453847 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin with didanosine-placebo
Number of subjects: 12
Study 3535814 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg deoxycholic acid
Number of subjects: 17
Study 3535814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31892654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger Training (HT)
Number of subjects: 40
Study 29097257 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) injections
Number of subjects: 0
Study 29097257 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 26467988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 19
Study 26467988 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 19
Study 25229980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg · kg(‐1) OM)
Number of subjects: 52
Study 25229980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 μg · kg(‐1) IND)
Number of subjects: 52
Study 25229980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral honey and intranasal saline)
Number of subjects: 52
Study 22369914 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LA volume (20.5±5.9 mL/m2)
Number of subjects: 246
Study 22369914 — intervention group
Group type: EXPERIMENTAL
Intervention: High LA volumes at baseline
Number of subjects: 246
Study 22369914 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak creatine kinase concentration
Number of subjects: 246
Study 22369914 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LA volumes at baseline
Number of subjects: 246
Study 18540006 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of lay health influencers in brief interventions for tobacco cessation
Number of subjects: 0
Study 18540006 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of material resources to health influencers
Number of subjects: 0
Study 18540006 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of a 'community of practice' among health influencers
Number of subjects: 0
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 15
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant 1 (low viscosity)
Number of subjects: 15
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant 2 (high viscosity)
Number of subjects: 15
Study 18677241 — intervention group
Group type: COMPARATOR
Intervention: No lubricant (baseline)
Number of subjects: 15
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with lubricants
Number of subjects: 15
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with saline
Number of subjects: 15
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dk lenses with lubricants
Number of subjects: 15
Study 18677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dk lenses with saline
Number of subjects: 15
Study 16431379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (one pill)
Number of subjects: 0
Study 16431379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (two pills)
Number of subjects: 0
Study 16431379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (both dosages)
Number of subjects: 0
Study 12817910 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 33
Study 12817910 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 33
Study 12845759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times a day
Number of subjects: 28
Study 12845759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times a day
Number of subjects: 28
Study 9216948 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen (HeO2) breathing during exercise
Number of subjects: 0
Study 9216948 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Anesthesia
Number of subjects: 0
Study 9216948 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation (Control)
Number of subjects: 0
Study 8354045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride effervescent granules
Number of subjects: 30
Study 8354045 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide-dimethicone combination
Number of subjects: 30
Study 3716912 — intervention group
Group type: EXPERIMENTAL
Intervention: Small, medium, and large puff instructions
Number of subjects: 0
Study 3716912 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled puff duration
Number of subjects: 0
Study 29605522 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based lower limb exercise intervention
Number of subjects: 576
Study 29605522 — intervention group
Group type: COMPARATOR
Intervention: Home-based upper limb exercise intervention
Number of subjects: 576
Study 29178746 — intervention group
Group type: EXPERIMENTAL
Intervention: Power toothbrush (Oral-B Professional Care 7000)
Number of subjects: 123
Study 29178746 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Lion Dentor Systema)
Number of subjects: 123
Study 23688422 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg fluticasone propionate (FP)
Number of subjects: 47
Study 23688422 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 47
Study 23688422 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 47
Study 23513282 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exercise (dual cycle ergometry) during a 2-hour oxygen prebreathe (F1O2 - 1.0)
Number of subjects: 13
Study 23513282 — intervention group
Group type: COMPARATOR
Intervention: Light arm exercise
Number of subjects: 13
Study 20651220 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat diet with exercise (SE)
Number of subjects: 8
Study 20651220 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet with exercise (UE)
Number of subjects: 8
Study 20651220 — intervention group
Group type: COMPARATOR
Intervention: High saturated fat diet with sedentary condition (SS)
Number of subjects: 8
Study 20651220 — intervention group
Group type: COMPARATOR
Intervention: High monounsaturated fat diet with sedentary condition (US)
Number of subjects: 8